Ibnsina Pharma results, Fiscal year 2025
Net profit, assets, equity and cash flow for Fiscal year 2025, against the same period a year earlier, from the published financial statements.
Net profit952 millionEGP · +54.9% vs the same period a year earlier
Total assets36.21 billionEGP · +26.4% vs the same period a year earlier
Shareholders' equity2.78 billionEGP · +37.1% vs the same period a year earlier
Operating cash flow-71.06 millionEGP · +93.5% vs the same period a year earlier
In short
- Ibnsina Pharma's net profit for Fiscal year 2025 was about 952 million EGP, up +54.9% from 615 million EGP in Fiscal year 2024.
- Total assets at the end of Fiscal year 2025 were about 36.21 billion EGP, and shareholders' equity about 2.78 billion EGP.
- Operating cash flow for Fiscal year 2025 was negative at 71.06 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2024Change
Net profit952 million615 million+54.9%
Gross profit6.48 billion4.53 billion+43.1%
Total assets36.21 billion28.64 billion+26.4%
Total liabilities33.43 billion26.61 billion+25.6%
Shareholders' equity2.78 billion2.03 billion+37.1%
Total liabilities and equity36.21 billion28.64 billion+26.4%
Operating cash flow-71.06 million-1.1 billion+93.5%
Investing cash flow-648 million-260 million−149.8%
Financing cash flow804 million891 million−9.8%
Net change in cash84.33 million-295 million+128.6%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Ibnsina Pharma's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy